The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Open accessAbstract
OBJECTIVE: To assess the efficacy and safety of galantamine in Alzheimer's disease at 3 months using flexible dose escalation. METHODS: A randomised, double blind, placebo controlled trial in 43 centres in the United States, Canada, Great Britain, South Africa, Australia, and New Zealand. Patients with probable Alzheimer's disease (n=386; 171 women) with a score of 11-24 on the mini mental state examination, and a score> or =12 on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog) were randomised to placebo, or galantamine escalated over 4 weeks to a maintenance dose of 24 or 32 mg/day. The primary outcome measures were the change in ADAS-cog score and the clinician's interview based impression of change plus caregiver input (CIBIC-plus) score. Activities of daily living (ADL) and behavioural symptoms were secondary outcomes. To compare the effects of highest levels of dosing, an observed cases (OC) analysis was undertaken, with classic intention to treat (ITT) and ITT with last observation carried forward (LOCF) as confirmatory analyses. RESULTS: At 3 months, galantamine (24-32 mg/day) produced a significantly better outcome on cognitive function than placebo (treatment difference=1.9 points on ADAS-cog, p=0.002) and a significantly better global response than placebo, as measured by CIBIC-plus (deterioration in 21% of patients on galantamine v 37% on placebo; p<0.001). Galantamine produced significant benefits on basic and instrumental ADL. Behavioural symptoms did not change significantly from baseline levels in either group. Adverse events (primarily gastrointestinal) were of mild to moderate intensity. There were no important differences between the OC, ITT, and ITT/LOCF analyses. Most patients (82%) who were maintained on the higher dose of galantamine completed the study. CONCLUSIONS: Patients on galantamine, compared with those on placebo, experienced benefits in cognitive function and instrumental and basic activities of daily living. Flexible dose escalation of galantamine was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Cited by
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Heinrich, M., & Lee Teoh, H. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.02.012 · Cited by 584
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
Qaseem, A., Snow, V., Cross, J. T., Forciea, M. A., Hopkins, R., Shekelle, P., Adelman, A., Mehr, D., Schellhase, K., Campos-Outcalt, D., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00008 · Cited by 354
Galantamine for Alzheimer's disease and mild cognitive impairment
Loy, C., & Schneider, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub3 · Cited by 322
Lilienfeld, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00221.x · Cited by 309
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Safety and efficacy of galantamine in subjects with mild cognitive impairment
Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303815.69777.26 · Cited by 266
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE
(1958) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1958.tb58406.x · Cited by 255
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
Clinical Pharmacokinetics of Galantamine
Farlow, M. R. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00005 · Cited by 134
Pharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
Difficult Behaviors in Long-term Care Patients With Dementia
Buhr, G. T., & White, H. K. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2006.12.012 · Cited by 97
d’Angremont, E., Begemann, M. J. H., van Laar, T., & Sommer, I. E. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1835 · Cited by 71
Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors
Leinonen, A., Koponen, M., & Hartikainen, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124500 · Cited by 64
Difficult Behaviors in Long-term Care Patients With Dementia
Buhr, G. T., & White, H. K. (2006) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2005.12.003 · Cited by 58
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
van Dyck, C. H., Mecca, A. P., O’Dell, R. S., Bartlett, H. H., Diepenbrock, N. G., Huang, Y., Hamby, M. E., Grundman, M., Catalano, S. M., Caggiano, A. O., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01382-2 · Cited by 29
Galantamine for dementia due to Alzheimer’s disease and mild cognitive impairment.
Lim, A. W. Y., Schneider, L., & Loy, C. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub4 · Cited by 24
Kaur, J., Melkani, I., Singh, A. P., Singh, A. P., & Bala, K. (2022) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v12i4.5426 · Cited by 13
Lewis, C. J., & de Grey, A. D. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2330425 · Cited by 10
Metadata
- Authors
- Rockwood, K.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2001-11-01
- Volume
- 71
- Issue
- 5
- Pages
- 589-595
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2152370183
- Cited by
- 279
- References
- 58
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.